FindTrial
Sign In

Outcome of Omega 3 FA and Punctal Plugs on Ocular Surface Disease

Outcome of Concomitant Use of Punctal Plugs and Omeg 3 Fatty Acids on Ocular Surface Disease in Patients Using Systemic Isotretinoin

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03686059
Enrollment
90
Registered
2018-09-26
Start date
2018-07-02
Completion date
2019-11-20
Last updated
2019-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Surface Disease

Brief summary

Ocular surface disease is a common adverse effect of systemic isotretinoin therapy. The investigators consider that punctal plugs and Omega 3 is a good line for treatment of ocular surface disease associated with systemic isotretinoin therapy

Detailed description

Subjective and objective evaluation of ocular surface disease was done at baseline ,1 and 3 months of the study .

Interventions

DRUGOmega 3

daily intake of 250 mg

DEVICEpunctal plug

punctal plug will be inserted in inferior punctum

Sponsors

Benha University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* systemic isotretinoin therapy

Exclusion criteria

* systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact lens wearer

Design outcomes

Primary

MeasureTime frameDescription
Change in Break up Time at baseline and during the study3 monthsfluorescein sodium stripes will be used for measurement of Break up Time in seconds

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026